TITLE

Once weekly exena-tide vs sitagliptin or pioglitazone for type 2 diabetes

PUB. DATE
October 2010
SOURCE
Internal Medicine Alert;10/29/2010, Vol. 32 Issue 20, p160
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the study which revealed that exenatide once weekly (EXEN-W) is more effective in managing type 2 diabetes as compared with sitagliptin (STG) or pioglitazone (PIO) implementations.
ACCESSION #
56440538

 

Related Articles

  • Intensive management of type 2 diabetes. Hines, Silvia E. // Patient Care;4/30/2000, Vol. 34 Issue 8, p91 

    Discusses the treatment of type 2 diabetes. Changes in treatment resulting from the introduction of four classes of oral antidiabetic agents; Glycemic control in type 2 diabetes; Treatment regimen development; Modifying and augmenting the regimen; Monitoring for the adjustment of medications;...

  • Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. Belkhadir, J.; El Ghomari, H.; Klocker, N.; Mikou, A.; Nasciri, M.; Sabri, M. // BMJ: British Medical Journal (International Edition);7/31/93, Vol. 307 Issue 6899, p292 

    Examines the effectiveness of glibenclamide in treating patients with non-insulin dependent diabetes fasting during Ramadan in Morocco. Assessment of the hypoglycemic events of patients; Correlation between fructosamine concentration and blood glucose concentration; Increase of creatinine...

  • Saxagliptin stacks up in Argentina, Brazil.  // PharmacoEconomics & Outcomes News;6/12/2010, Issue 605, p8 

    The article offers information on three Bristol-Myers Squibb-supported studies, which examined the cost effectiveness of saxagliptin in the treatment of type 2 diabetes mellitus (DM) patients in Argentina and Brazil.

  • Dapagliflozin maintains HR-QOL in diabetes.  // PharmacoEconomics & Outcomes News;10/27/2012, Issue 665, p10 

    The article reports on an international, double-blind clinical trial on the impact of dapagliflozin in health-related quality of life (HR-QOL) of patients with type 2 diabetes.

  • Are TZDs still useful? Friedman, Theodore C.; Garber, Alan J. // Endocrine Today;Jul2013, Vol. 12 Issue 7, p11 

    The authors express their views on the relevance of thiazolidinedione (TZD) pioglitazone in the treatment of patients with type two diabetes despite new diabetes drugs in the market as of July 2013.

  • Patients willing to pay extra for liraglutide over glimepiride.  // PharmacoEconomics & Outcomes News;7/24/2010, Issue 608, p9 

    The article discusses research on the willingness of type 2 diabetes mellitus patients to pay extra for liraglutide over glimepiride, referencing a study by J. Jendle and colleagues presented that the 70th Annual Scientific Sessions of the American Diabetes Association.

  • Investigational SGLT2 inhibitor lowered BP regardless of weight, HbA1c.  // Cardiology Today;Nov2012, Vol. 15 Issue 11, p14 

    The article discusses a study which investigated the efficacy of empagliflozin in patients with type 2 diabetes.

  • Rosiglitazone: A new thiazolidinedione for treatment of type 2 diabetes. Amato, Paul V. // Formulary;Oct99, Vol. 34 Issue 10, p825 

    Rosiglitazone is an orally active antidiabetic agent of the thiazolidinedione class. It was approved by the FDA in May as monotherapy and in combination with metformin for the treatment of type 2 diabetic patients. As a potent agonist of peroxisome proliferator-activated receptor gamma,...

  • New oral therapies for type 2 diabetes. Purnell, Jonathan Q.; Hirsch, Irl B. // American Family Physician;11/1/1997, Vol. 56 Issue 7, p1835 

    Provides information on several oral agents for the treatment of type two diabetes available in the United States. Side effects of metformin, acarbose, troglitazone; Its mechanism of action of the drugs; Adverse effects of the drugs.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics